Coya Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
COYA Nasdaq 2836 coyatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coya Therapeutics, Inc.

iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025 - Jun 18th, 2025 7:00 am
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025 - Jun 18th, 2025 6:15 am
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations - Jun 2nd, 2025 6:00 am
Coya Therapeutics First Quarter 2025 Earnings: Misses Expectations - May 19th, 2025 6:28 am
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - May 16th, 2025 8:53 am
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - May 13th, 2025 6:00 am
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - May 8th, 2025 6:15 am
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? - Apr 29th, 2025 7:40 am
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Apr 24th, 2025 6:15 am
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Apr 23rd, 2025 7:55 am
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - Apr 21st, 2025 7:51 am
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - Apr 17th, 2025 5:00 am
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Apr 11th, 2025 1:02 pm
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - Apr 1st, 2025 6:15 am
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Mar 27th, 2025 10:00 am
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Mar 27th, 2025 7:55 am
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Mar 27th, 2025 7:40 am
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Mar 26th, 2025 6:15 am
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Mar 20th, 2025 6:00 am
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Mar 18th, 2025 6:15 am